PURPOSE: To independently validate two biomarkers, a 44-gene DNA damage immune response (DDIR) signature and stromal tumor-infiltrating lymphocytes (sTILs), as prognostic markers in patients with triple-negative breast cancer (TNBC) treated with adjuvant doxorubicin (A) and cyclophosphamide (C) in SWOG 9313. METHODS: Four hundred twenty-five centrally determined patient cases with TNBC from S9313 were identified. DDIR signature was performed on RNA isolated from formalin-fixed paraffin-embedded tumor tissue, and samples were classified as DDIR negative or positive using predefined cutoffs. Evaluation of sTILs was performed as described previously. Markers were tested for prognostic value for disease-free survival (DFS) and overall survival (OS) using Cox regression models adjusted for treatment assignment, nodal status, and tumor size. RESULTS: Among 425 patients with TNBC, 33% were node positive. DDIR was tested successfully in 90% of patients (381 of 425), 62% of which were DDIR signature positive. DDIR signature positivity was associated with improved DFS (hazard ratio [HR], 0.67; 95% CI, 0.48 to 0.92; P = .015) and OS (HR, 0.61; 95% CI, 0.43 to 0.89; P = .010). sTILs density assessment was available in 99% of patients and was associated with improved DFS (HR, 0.70; 95% CI, 0.51 to 0.96; P = .026 for sTILs density ≥ 20% v < 20%) and OS (HR, 0.59; 95% CI, 0.41 to 0.85; P = .004 for sTILs density ≥ 20% v < 20%). DDIR signature score and sTILs density were moderately correlated (r = 0.60), which precluded statistical significance for DFS in a joint model. Three-year DFS and OS in a subgroup of patients with DDIR positivity and T1c/T2N0 disease were 88% and 94%, respectively. CONCLUSION: The prognostic role of sTILs and DDIR in early-stage TNBC was confirmed. DDIR signature conferred improved prognosis in two thirds of patients with TNBC treated with adjuvant AC. DDIR signature has the potential to stratify outcome and to identify patients with less projected benefit after AC chemotherapy.
PURPOSE: To independently validate two biomarkers, a 44-gene DNA damage immune response (DDIR) signature and stromal tumor-infiltrating lymphocytes (sTILs), as prognostic markers in patients with triple-negative breast cancer (TNBC) treated with adjuvant doxorubicin (A) and cyclophosphamide (C) in SWOG 9313. METHODS: Four hundred twenty-five centrally determined patient cases with TNBC from S9313 were identified. DDIR signature was performed on RNA isolated from formalin-fixed paraffin-embedded tumor tissue, and samples were classified as DDIR negative or positive using predefined cutoffs. Evaluation of sTILs was performed as described previously. Markers were tested for prognostic value for disease-free survival (DFS) and overall survival (OS) using Cox regression models adjusted for treatment assignment, nodal status, and tumor size. RESULTS: Among 425 patients with TNBC, 33% were node positive. DDIR was tested successfully in 90% of patients (381 of 425), 62% of which were DDIR signature positive. DDIR signature positivity was associated with improved DFS (hazard ratio [HR], 0.67; 95% CI, 0.48 to 0.92; P = .015) and OS (HR, 0.61; 95% CI, 0.43 to 0.89; P = .010). sTILs density assessment was available in 99% of patients and was associated with improved DFS (HR, 0.70; 95% CI, 0.51 to 0.96; P = .026 for sTILs density ≥ 20% v < 20%) and OS (HR, 0.59; 95% CI, 0.41 to 0.85; P = .004 for sTILs density ≥ 20% v < 20%). DDIR signature score and sTILs density were moderately correlated (r = 0.60), which precluded statistical significance for DFS in a joint model. Three-year DFS and OS in a subgroup of patients with DDIR positivity and T1c/T2N0 disease were 88% and 94%, respectively. CONCLUSION: The prognostic role of sTILs and DDIR in early-stage TNBC was confirmed. DDIR signature conferred improved prognosis in two thirds of patients with TNBC treated with adjuvant AC. DDIR signature has the potential to stratify outcome and to identify patients with less projected benefit after AC chemotherapy.
Authors: Lisa M McShane; Douglas G Altman; Willi Sauerbrei; Sheila E Taube; Massimo Gion; Gary M Clark Journal: J Natl Cancer Inst Date: 2005-08-17 Impact factor: 13.506
Authors: Joseph A Sparano; Molin Wang; Silvana Martino; Vicky Jones; Edith A Perez; Tom Saphner; Antonio C Wolff; George W Sledge; William C Wood; Nancy E Davidson Journal: N Engl J Med Date: 2008-04-17 Impact factor: 91.245
Authors: R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard Journal: Lancet Date: 2011-12-05 Impact factor: 79.321
Authors: Eileen E Parkes; Steven M Walker; Laura E Taggart; Nuala McCabe; Laura A Knight; Richard Wilkinson; Karen D McCloskey; Niamh E Buckley; Kienan I Savage; Manuel Salto-Tellez; Stephen McQuaid; Mary T Harte; Paul B Mullan; D Paul Harkin; Richard D Kennedy Journal: J Natl Cancer Inst Date: 2016-10-05 Impact factor: 13.506
Authors: Sylvia Adams; Robert J Gray; Sandra Demaria; Lori Goldstein; Edith A Perez; Lawrence N Shulman; Silvana Martino; Molin Wang; Vicky E Jones; Thomas J Saphner; Antonio C Wolff; William C Wood; Nancy E Davidson; George W Sledge; Joseph A Sparano; Sunil S Badve Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: E H Lips; L Mulder; A Oonk; L E van der Kolk; F B L Hogervorst; A L T Imholz; J Wesseling; S Rodenhuis; P M Nederlof Journal: Br J Cancer Date: 2013-04-04 Impact factor: 7.640
Authors: Jude M Mulligan; Laura A Hill; Steve Deharo; Gareth Irwin; David Boyle; Katherine E Keating; Olaide Y Raji; Fionnuala A McDyer; Eamonn O'Brien; Max Bylesjo; Jennifer E Quinn; Noralane M Lindor; Paul B Mullan; Colin R James; Steven M Walker; Peter Kerr; Jacqueline James; Timothy S Davison; Vitali Proutski; Manuel Salto-Tellez; Patrick G Johnston; Fergus J Couch; D Paul Harkin; Richard D Kennedy Journal: J Natl Cancer Inst Date: 2014-01 Impact factor: 13.506
Authors: Samuel F Bakhoum; Bryan Ngo; Ashley M Laughney; Julie-Ann Cavallo; Charles J Murphy; Peter Ly; Pragya Shah; Roshan K Sriram; Thomas B K Watkins; Neil K Taunk; Mercedes Duran; Chantal Pauli; Christine Shaw; Kalyani Chadalavada; Vinagolu K Rajasekhar; Giulio Genovese; Subramanian Venkatesan; Nicolai J Birkbak; Nicholas McGranahan; Mark Lundquist; Quincey LaPlant; John H Healey; Olivier Elemento; Christine H Chung; Nancy Y Lee; Marcin Imielenski; Gouri Nanjangud; Dana Pe'er; Don W Cleveland; Simon N Powell; Jan Lammerding; Charles Swanton; Lewis C Cantley Journal: Nature Date: 2018-01-17 Impact factor: 49.962
Authors: Tesa M Severson; Denise M Wolf; Christina Yau; Justine Peeters; Diederik Wehkam; Philip C Schouten; Suet-Feung Chin; Ian J Majewski; Magali Michaut; Astrid Bosma; Bernard Pereira; Tycho Bismeijer; Lodewyk Wessels; Carlos Caldas; René Bernards; Iris M Simon; Annuska M Glas; Sabine Linn; Laura van 't Veer Journal: Breast Cancer Res Date: 2017-08-25 Impact factor: 6.466
Authors: Kim R M Blenman; Michal Marczyk; Thomas Karn; Tao Qing; Xiaotong Li; Vignesh Gunasekharan; Vesal Yaghoobi; Yalai Bai; Eiman Y Ibrahim; Tristen Park; Andrea Silber; Denise M Wolf; Emily Reisenbichler; Carsten Denkert; Bruno V Sinn; Mariya Rozenblit; Julia Foldi; David L Rimm; Sibylle Loibl; Lajos Pusztai Journal: Clin Cancer Res Date: 2022-06-13 Impact factor: 13.801
Authors: Alice Y Ho; Jean L Wright; Rachel C Blitzblau; Robert W Mutter; Dan G Duda; Larry Norton; Aditya Bardia; Laura Spring; Steven J Isakoff; Jonathan H Chen; Clemens Grassberger; Jennifer R Bellon; Sushil Beriwal; Atif J Khan; Corey Speers; Samantha A Dunn; Alastair Thompson; Cesar A Santa-Maria; Ian E Krop; Elizabeth Mittendorf; Tari A King; Gaorav P Gupta Journal: Int J Radiat Oncol Biol Phys Date: 2020-05-14 Impact factor: 7.038
Authors: Priyanka Sharma; Bruce F Kimler; Anne O'Dea; Lauren Nye; Yen Y Wang; Rachel Yoder; Joshua M Staley; Lindsey Prochaska; Jamie Wagner; Amanda L Amin; Kelsey Larson; Christa Balanoff; Manana Elia; Gregory Crane; Sheshadri Madhusudhana; Marc Hoffmann; Maureen Sheehan; Roberto Rodriguez; Karissa Finke; Rajvi Shah; Deepti Satelli; Anuj Shrestha; Larry Beck; Richard McKittrick; Robert Pluenneke; Vinay Raja; Venkatadri Beeki; Larry Corum; Jaimie Heldstab; Stephanie LaFaver; Micki Prager; Milind Phadnis; Dinesh Pal Mudaranthakam; Roy A Jensen; Andrew K Godwin; Roberto Salgado; Kathan Mehta; Qamar Khan Journal: Clin Cancer Res Date: 2020-11-18 Impact factor: 13.801
Authors: Yuquan Qian; Jimmy Daza; Timo Itzel; Johannes Betge; Tianzuo Zhan; Frederik Marmé; Andreas Teufel Journal: Cells Date: 2021-03-15 Impact factor: 6.600
Authors: Eileen E Parkes; Kienan I Savage; Tong Lioe; Clinton Boyd; Sophia Halliday; Steven M Walker; Keith Lowry; Laura Knight; Niamh E Buckley; Andrena Grogan; Gemma E Logan; Alison Clayton; Jane Hurwitz; Stephen J Kirk; Jiamei Xu; Fatima Abdullahi Sidi; Matthew P Humphries; Victoria Bingham; Jaqueline A James; Colin R James; D Paul Harkin; Richard D Kennedy; Stuart A McIntosh Journal: Br J Cancer Date: 2021-11-02 Impact factor: 7.640
Authors: Fangfang Liu; Thomas Hardiman; Kailiang Wu; Jelmar Quist; Patrycja Gazinska; Tony Ng; Arnie Purushotham; Roberto Salgado; Xiaojing Guo; Sarah E Pinder; Anita Grigoriadis Journal: NPJ Breast Cancer Date: 2021-07-05